These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 9788580)

  • 1. Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels.
    de Vos D; Slee PH; Briggs RJ; Stevenson D
    Cancer Chemother Pharmacol; 1998; 42(6):512-4. PubMed ID: 9788580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients.
    Kiyotani K; Mushiroda T; Imamura CK; Tanigawara Y; Hosono N; Kubo M; Sasa M; Nakamura Y; Zembutsu H
    Breast Cancer Res Treat; 2012 Jan; 131(1):137-45. PubMed ID: 21947681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Excretion of hydroxylated metabolites of tamoxifen in human bile and urine.
    Kisanga ER; Mellgren G; Lien EA
    Anticancer Res; 2005; 25(6C):4487-92. PubMed ID: 16334131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomonitoring of urinary tamoxifen and its metabolites from breast cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrometry.
    Carter SJ; Li XF; Mackey JR; Modi S; Hanson J; Dovichi NJ
    Electrophoresis; 2001 Aug; 22(13):2730-6. PubMed ID: 11545399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
    Dahmane E; Mercier T; Zanolari B; Cruchon S; Guignard N; Buclin T; Leyvraz S; Zaman K; Csajka C; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Dec; 878(32):3402-14. PubMed ID: 21094101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules.
    Fabian C; Sternson L; Barnett M
    Cancer Treat Rep; 1980; 64(6-7):765-73. PubMed ID: 7427961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
    Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
    Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients.
    Soininen K; Kleimola T; Elomaa I; Salmo M; Rissanen P
    J Int Med Res; 1986; 14(3):162-5. PubMed ID: 3522312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens].
    Masuoka H; Mori M; Nomura N; Sakurai M; Yoshida K; Usuda N; Shirai H; Shimokawara I; Asaishi K
    Gan To Kagaku Ryoho; 2002 Jun; 29(6):881-7. PubMed ID: 12090039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of drug metabolites in human plasma or serum integrating metabolite prediction, LC-HRMS and untargeted data processing.
    Jacobs PL; Ridder L; Ruijken M; Rosing H; Jager NG; Beijnen JH; Bas RR; van Dongen WD
    Bioanalysis; 2013 Sep; 5(17):2115-28. PubMed ID: 23962251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.
    Lien EA; Søiland H; Lundgren S; Aas T; Steen VM; Mellgren G; Gjerde J
    Breast Cancer Res Treat; 2013 Sep; 141(2):243-8. PubMed ID: 23996142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques.
    Teunissen SF; Rosing H; Seoane MD; Brunsveld L; Schellens JH; Schinkel AH; Beijnen JH
    J Pharm Biomed Anal; 2011 Jun; 55(3):518-26. PubMed ID: 21392921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
    Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
    Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer.
    Fotoohi AK; Karim H; Lafolie P; Pohanka A; Östervall J; Hatschek T; Vitols S
    Ther Drug Monit; 2016 Apr; 38(2):239-45. PubMed ID: 26485084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin.
    Premkumar VG; Yuvaraj S; Vijayasarathy K; Gangadaran SG; Sachdanandam P
    Basic Clin Pharmacol Toxicol; 2007 Jun; 100(6):387-91. PubMed ID: 17516992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.
    Ellmén J; Hakulinen P; Partanen A; Hayes DF
    Breast Cancer Res Treat; 2003 Nov; 82(2):103-11. PubMed ID: 14692654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours.
    MacCallum J; Cummings J; Dixon JM; Miller WR
    Br J Cancer; 2000 May; 82(10):1629-35. PubMed ID: 10817496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Plasma concentrations of toremifene citrate and N-desmethyltoremifene in postmenopausal patients with breast cancer--comparison of 120 mg of toremifene citrate administered once a day and divided into 3 separate doses (t.i.d.)].
    Shiba E; Watanabe T; Taguchi T; Tsukamoto F; Noguchi S
    Gan To Kagaku Ryoho; 2000 Feb; 27(2):245-9. PubMed ID: 10700895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.